Abstract
Pharmacotherapy in Ovarian Carcinoma Although recent years have seen considerable progress in the treatment of primary and recurrent ovarian carcinoma, the mortality rate continues to be very high. Possibilities for improvement include compliance with the current treatment recommendations both in the surgical and medical areas, as well as the participation in clinical studies or treatment in study centers.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carboplatin / administration & dosage
-
Carboplatin / therapeutic use
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Clinical Trials, Phase III as Topic
-
Drug Resistance, Neoplasm
-
Female
-
Follow-Up Studies
-
Humans
-
Neoplasm Recurrence, Local / drug therapy
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / surgery
-
Paclitaxel / administration & dosage
-
Paclitaxel / therapeutic use
-
Prognosis
-
Quality of Life
-
Time Factors
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Carboplatin
-
Paclitaxel
-
Cisplatin